Clinical Trials

Inclusion Criteria:

• Age ≥ 18 years old.
• ***Histologically documented Squamous Cell Carcinoma of the oropharynx (AJCC v7** Stage III-IV A,B).
• *Tumor tissue (primary or cervical metastasis) available for human papilloma virus (HPV) and/or p16 (in situ hybridization (ISH), immunohistochemistry (IHC) or genotyping testing).
• If you do not have enough leftover tumor tissue available, you will have a tumor biopsy for tumor marker testing.
• Eastern Cooperative Oncology Group (ECOG) performance status= 0, 1, or 2.
• Negative pregnancy test for women of child bearing potential.
• Concurrent chemotherapy.
• Bilateral neck radiation.

Exclusion Criteria:

• Previous radiation treatment for head and neck mucosal primary cancers within the past 5 years (i.e., oropharynx, nasopharynx, hypopharynx, larynx, and oral cavity).
• Pregnant or breast-feeding females.
• Clinically significant uncontrolled major cardiac, respiratory, renal, hepatic, gastrointestinal or hematologic disease but not limited to:
  • Symptomatic congestive heart failure, unstable angina, or cardiac dysrrhythmia not controlled by pacer device;
  • No myocardial infarction within 3 months of registration.
• Distant metastases (AJCC v7** Stage IV C, any T, any N and M1).
• Previous surgical resection or neck dissection for oropharyngeal cancer, administered with therapeutic intent.

*    If you do not have enough leftover tumor tissue available, you will have a tumor biopsy for tumor marker testing.
**  American Joint Committee on Cancer (AJCC) 7th edition.
*** For clinically visible or radiographically diagnosed oropharynx cancer, neck mass biospy/US FNA is acceptable.